Related Experiment Videos

Role for beta-blockers in the management of diabetic kidney disease

George L Bakris1

  • 1Department of Preventive Medicine, Rush-Presbyterian-St. Luke's Medical Center, 1700 West Van Buren, Suite 470, Chicago, IL 60612, USA. George_L_Bakris@rsh.net

American Journal of Hypertension
|September 27, 2003
PubMed

Insights

Managing hypertension in diabetic kidney disease is crucial for slowing disease progression and reducing cardiovascular events. Optimal treatment involves renin-angiotensin system blockers combined with other agents, including beta-blockers for blood pressure control and heart protection.

Area of Science:

  • Nephrology
  • Cardiology
  • Endocrinology

Background:

  • Diabetes is the leading cause of end-stage renal disease (ESRD) in the US.
  • Diabetic renal disease patients often have co-existing hypertension and cardiovascular (CV) risk factors.
  • Cardiovascular events are the primary cause of mortality in this population.

Purpose of the Study:

  • To highlight the relevance of antihypertensive therapy in diabetic patients.
  • To outline treatment goals: lowering blood pressure, slowing kidney disease progression, and reducing CV event risk.
  • To discuss optimal antihypertensive strategies for patients with diabetic kidney disease.

Main Methods:

  • Review of data from numerous randomized clinical trials.
  • Focus on recommended target blood pressure (<130/80 mm Hg) for chronic kidney disease patients.
  • Emphasis on combination antihypertensive therapy.

Main Results:

  • Most patients require multiple antihypertensive agents (often >2) to achieve target blood pressure.
  • Agents blocking the renin-angiotensin system are recommended.
  • Combination therapy with diuretics, beta-blockers, or calcium channel blockers is advised.

Conclusions:

  • Beta-blockers play a dual role in managing diabetic kidney disease: achieving blood pressure targets and providing cardioprotection.
  • Comprehensive management of hypertension is essential for improving outcomes in diabetic renal disease.
  • Targeted antihypertensive therapy reduces kidney disease progression and cardiovascular risk.

Related Concept Videos

Antihypertensive Drugs: Action of &#946;1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Types of &#946;-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Adrenergic Antagonists: Pharmacological Actions of &#946;-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...